Preston Sprenkle, MD – Championing Prostate Cancer Diagnostics, Focal Therapy, and Patient Education
Preston Sprenkle, MD, is an associate professor of urology at the Yale School of Medicine and chief of the Division of Urology at the Veterans Affairs (VA) Connecticut Healthcare System. An expert in the treatment of urologic cancers, Dr. Sprenkle has pioneered the use of the Artemis Device—a 3-dimensional imaging technology for diagnosing cancerous tumors in the prostate—as well as focal therapy in prostate cancer. ...
Advertisement
Advertisement
Latest News
Amar Kishan, MD gives an overview of the MIRAGE trial that compared MRI-guided and CT-guided SBRT for prostate cancer.
Can using a hyaluronic acid spacer mitigate rectal toxicity and reduce the gastrointestinal toxicity associated with RT?
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Video Insights
Clinical discussions with experts in the field
